I don't blame retail or regular shareholders. It is the short and distort groups such as those that make a living hitting companies with lies and distortion to profit from shorting. It started here in Jan 2015 and continues. They caused the drop in share price which in turn affected everything else.
The company even won a case dismissal last year against a suit based on one of the hits. But, the damage has been done. I don't see a substantial change in share price until a partnership or sale of an asset or the company.
Like I said, legitimate complaints need to be aired, but, that is a different thing from what I'm speaking of. Making money hurting new biotech with lies is despicable. The potential patients are the true losers.
In Reply to 'Amatuer17'
You cannot blame people - this is just investment
The retail SH do not have direct impact on drug development - it is management that controls everything.
Mgmt can blame themselves for not being able manage their business environment, not getting right funding to start trials on time, not being anle to find partners to move faster, fda for not moving fast enough.
There are enough retail investors in market and if mgmt doing ok they will support.
S
News 
Market Data 
Discover 
